To accelerate NF research, CTF launched the Clinical Research Award (CRA) program in 2007 to support early stage pilot clinical trials of candidate therapeutics or interventions for treatment of manifestations of NF1, NF2 and schwannomatosis. In addition, these awards support innovative clinical trial enabling studies.
It is hoped that applications for Clinical Research Awards will be broad-thinking, novel ideas. Examples of projects encouraged may include but are not limited to the following:
- Preclinical/clinical collaborative studies. Note that all studies must include a clinical element – preclinical-only studies are not eligible
- Pilot clinical trials (CTF leverages our relationship with industry or larger funding organizations to provide drug at no cost to successful applicants.)
- Clinical enabling studies such as biomarker and patient stratification that may better inform and help accelerate a clinical trial.
It is anticipated that CTF will fund up to three Clinical Research Awards of up to $150,000 (including overheads and indirect costs).